XORTX Therapeutics (CSE:XRX; OTCQB:XRTXF), in conjunction with partner, Teijin Pharma, posted positive, statistically significant results with its TMX-049 drug candidate in a U.S. Phase 2 clinical trial in individuals with Type 2 diabetic nephropathy.
The study was designed to test whether TMX-049 over a 12-week treatment period would decrease uric acid levels, and would provide a safe and effective therapeutic approach to decreasing albuminuria.
Study results showed that in patients with Type 2 diabetic nephropathy, TMX-049 could be safely administered to individuals in the tested dose range and was well tolerated; oral daily doses of TMX-049 could substantially and significantly decrease serum uric acid; and oral daily doses of TMX-049 decreased urinary albumin proteinuria to a substantial and statistically significant degree.
“In the opinion of XORTX, TMX-049 is a leading next generation candidate xanthine oxidase inhibitor, with a desirable combination of strong clinical safety record and potent uric acid lowering capability,” Dr. Allen Davidoff, CEO, said in a statement.
“The results of this study substantially increase the probability of advancing a first-in-class and best-in-class drug to slow and reverse progression of kidney disease in individuals with Type 2 diabetic nephropathy,” he added.